January -
- Total revenue
SEK 4,925 M (3,661), +35 per cent, +24 per cent at constant exchange rates (CER) - Haematology revenue
SEK 2,499 M (1,877), +25 per cent at CER of which Elocta®SEK 1,024 M (857), +15 per cent at CER; Alprolix®SEK 419 M (413), -3 per cent at CER; Doptelet®SEK 593 M (180), +197 per cent at CER and Aspaveli®/Empaveli(TM)SEK 4 M (-) - Immunology revenue
SEK 2,119 M (1,554), +24 per cent at CER of which Kineret®SEK 645 M (542), +11 per cent at CER; Synagis®SEK 1,286 M (879), +31 per cent at CER and Gamifant®SEK 189 M (133), +27 per cent at CER - EBITA
1 SEK 1,290 M (1,484), EBITA margin1 26 percent (41) - Items affecting comparability2 of
SEK -661 M included a provision for expected credit losses inRussia ofSEK -157 M. Restructuring comprised contract manufacturing closure ofSEK -360 M, site simplification ofSEK -72 M and efficiency programmes ofSEK -72 M. Excluding these costs, the EBITA adjusted amounted toSEK 1,951 M corresponding to an EBITA margin adjusted1 of 40 percent (41) - Efficiency programmes will focus resources into core areas, simplify the organisation and adjust the cost base to enable Sobi to continue sustainable growth and margin improvement over time
- EBIT
SEK 776 M (1,034), EBIT adjusted1 SEK 1,437 M (1,034) - Earnings per share (EPS) before dilution
SEK 1.84 (2.36), EPS before dilution adjustedSEK 3.67 (2.36) - Cash flow from operating activities
SEK 1,644 M (1,699) - Efanesoctocog alfa positive XTEND-1 phase 3 study readout, Gamifant approval in
China and other encouraging pipeline milestones
2022 outlook
- Revenue is anticipated to grow by a mid to high single-digit percentage at CER (unchanged)
- EBITA margin is anticipated to be at a low 30s percentage of revenue (now based on EBITA margin adjusted)
Financial summary
Investors, analysts and media are invited to participate in a conference call which will include a presentation of the results and a Q&A session at
The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com prior to the conference call.
To participate in the conference call, please call:
US: +1 631 913 1422 (toll) PIN: 27168016#
Sobi®
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Providing sustainable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,600 employees across
This information is information that Sobi is obliged to make public pursuant to the
Contacts
For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.
Head of Communication and Investor Relations
Postal address SE-112 76
Phone: 46 8 697 20 00 www.sobi.com
https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-publishes-q1-2022-report,c3554965
https://mb.cision.com/Main/14266/3554965/1570363.pdf
https://news.cision.com/swedish-orphan-biovitrum-ab/i/3554965-0-png,c3043036
(c) 2022 Cision. All rights reserved., source